Search results for "ExAC"
showing 10 items of 1440 documents
Cardiovascular Events During and After Bronchiectasis Exacerbations and Long-term Mortality.
2022
ABSTRACT Background Population-based and retrospective studies have shown that risk for cardiovascular events such as arrythmias, ischemic episodes or heart failure, increase during and after bronchiectasis exacerbations. Research Question What are the risk factors for cardiovascular events (CVE) during and after bronchiectasis exacerbations and its impact on mortality? Study Design and Methods This was a post-hoc retrospective analysis of a prospective observational study of 250 patients with bronchiectasis at two tertiary care hospitals. Only the first exacerbation was considered for each patient, collecting demographic, comorbidity, and severity data. The main outcomes were the appearanc…
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy
2017
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies. This secondary analysis assessed reslizumab's efficacy in patients receiving baseline treatment per Global Initiative for Asthma (GINA) Step 4 and Step 5 guidelines. Pooled data from duplicate, Phase III, reslizumab versus placebo studies in patients with severe eosinophilic asthma (blood eosinophils ≥400 cells·µL−1) were stratified by baseline therapy. Efficacy assessments were exacerbation rates and changes from baseline forced expiratory volume in …
Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthma.
2005
Exacerbations are an important cause of the morbidity and mortality associated with asthma and chronic obstructive pulmonary disease. Newer therapies include long-acting beta(2)-agonists, which are more effective than short-acting bronchodilators. Inhaled corticosteroids and, in asthma, leukotriene receptor antagonists may have roles in the early phase of exacerbation as an alternative to or added to oral prednisolone. In the future, combinations of long-acting beta(2)-agonists and anticholinergic bronchodilators may offer additive clinical benefits. However, although the treatment and prevention of exacerbations of chronic obstructive pulmonary disease and asthma have been improved by usin…
Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement
2015
Background Exacerbations are a key outcome in clinical research, providing patient-relevant information about symptomatic control, health state and disease progression. Generally considered as an episode of (sub)acute deterioration of respiratory symptoms, a precise, clinically useful definition is needed for use in clinical trials. Aim and methods Focussing on moderate exacerbations, this opinion piece reviews landmark trials and current guidelines to provide a practical definition of a moderate exacerbation. Specifically, we adapt the ATS/ERS consensus statement of terminology Reddel et al. (2009) [1] which provides a conceptual (or 'theoretical') definition for moderate exacerbations, to…
Response to mepolizumab treatment is sustained across 4-weekly dosing periods
2020
Background Mepolizumab (100 mg delivered s.c. every 4 weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticosteroids, and improve asthma control and symptoms. However, data on the durability of the response to mepolizumab during dosing periods are limited. The aim of this study was to investigate the efficacy profile in patients with severe eosinophilic asthma over the 4-weekly dosing period for various fixed mepolizumab doses. Methods This was a post hoc analysis of data from the phase IIb/III DREAM study. Patients ≥12 years of age with severe eosinophil…
Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
2021
Moritz Z Kayser,1 Nora Drick,1 Katrin Milger,2,3 Jan Fuge,1,4 Nikolaus Kneidinger,2,3 Stephanie Korn,5 Roland Buhl,6 Jürgen Behr,2,3 Tobias Welte,1,4 Hendrik Suhling1 1Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; 2Department of Medicine V, University Hospital, LMU, Munich, Germany; 3Comprehensive Pneumology Center-Munich (CPCâM), Member of the German Center for Lung Research (DZL), Munich, Germany; 4Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany; 5Clinical Research Centre for Respiratory Medicine, Mainz, Germany; 6Pulmonary Department, Mainz Universit…
Moving from the Oslerian paradigm to the postgenomic era: Are asthma and COPD outdated terms?
2016
In the majority of cases, asthma and chronic obstructive pulmonary disease (COPD) are two clearly distinct disease entities. However, in some patients there may be significant overlap between the two conditions. This constitutes an important area of concern because these patients are generally excluded from randomised controlled trials (mostly because of smoking history in the case of asthma or because of significant bronchodilator reversibility in the case of COPD). As a result, their pathobiology, prognosis and response to therapy are largely unknown. This may lead to suboptimal management and can limit the development of more personalised therapeutic options. Emerging genetic and molecul…
Homomorphisms between Algebras of Holomorphic Functions
2014
For two complex Banach spaces X and Y, in this paper, we study the generalized spectrum M-b(X,Y) of all nonzero algebra homomorphisms from H-b(X), the algebra of all bounded type entire functions on X into H-b(Y). We endow M-b(X,Y) with a structure of Riemann domain over L(X*,Y*) whenever.. is symmetrically regular. The size of the fibers is also studied. Following the philosophy of ( Aron et al., 1991), this is a step to study the set M-b,M-infinity (X,B-Y) of all nonzero algebra homomorphisms from Hb(b) (X) into H-infinity (B-Y) of bounded holomorphic functions on the open unit ball of Y and M-infinity(B-X,B-Y) of all nonzero algebra homomorphisms from H-infinity(B-X) into H infinity (B-Y…
FREDHOLM THEORY FOR DEGENERATE PSEUDODIFFERENTIAL OPERATORS ON MANIFOLDS WITH FIBERED BOUNDARIES
2001
We consider the calculus Ψ*,* de(X, deΩ½) of double-edge pseudodifferential operators naturally associated to a compact manifold X whose boundary is the total space of a fibration. This fits into the setting of boundary fibration structures, and we discuss the corresponding geometric objects. We construct a scale of weighted double-edge Sobolev spaces on which double-edge pseudodifferential operators act as bounded operators, characterize the Fredholm elements in Ψ*,* de(X) by means of the invertibility of an appropriate symbol map, and describe a K-theoretical formula for the Fredholm index extending the Atiyah–Singer formula for closed manifolds. The algebra of operators of order (0, 0) i…
The snail lemma for internal groupoids
2019
Abstract We establish a generalized form both of the Gabriel-Zisman exact sequence associated with a pointed functor between pointed groupoids, and of the Brown exact sequence associated with a fibration of pointed groupoids. Our generalization consists in replacing pointed groupoids with groupoids internal to a pointed regular category with reflexive coequalizers.